Cosmos Health Signs LOI to Acquire Doc Pharma S.A., Boosting Assets by $24M and Adding $6.7M in Revenue
COSM is trading near its 52-week low of $0.195 (6.4% above the low) on elevated volume (2.5× avg).
Summary
Cosmos Health has signed a non-binding Letter of Intent to acquire Doc Pharma S.A., a European GMP pharmaceutical manufacturer. This proposed acquisition is highly material, with Doc Pharma bringing an estimated $24 million in assets and $6.7 million in average annual revenue. The deal aims to boost production capacity, expand the product portfolio, and improve profitability, which is critical given Cosmos Health's recent going concern warnings and increased cash burn. The transaction is a related-party deal requiring independent review and shareholder approval, with no assurance of completion.
At the time of this announcement, COSM was trading at $0.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $0.20 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.